Skip to main content

Table 3 Muscular and cutaneous activity evaluation and medications in use by JDM patients at each study visit

From: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

Study visitsa V1b V2 V3 V4 V1b V2 V3 V4 V1b V2 V3 V4
JDM groups A + B (n = 27) A + B (n = 27) A + B (n = 25) A + B (n = 20) C (n = 15) C (n = 15) C (n = 15) C (n = 6) Total (n = 42) Total (n = 42) Total (n = 40) Total (n = 26)
Muscular activity
 CMAS, median 52 52 52 52 37 42 46 43 50 51,5 50 50
Cutaneous activity
 Rash, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (60) 7 (46.7) 4 (26.7) 1 (16.7) 9 (21.4) 7 (16.7) 4 (10) 1 (3.8)
 Gottron’s papules, n (%) 0 (0.0) 0 (0.0) 1 (4.0) 0 (0.0) 12 (80) 9 (60) 9 (60) 3 (50) 12 (28.6) 9 (21.4) 10 (25) 3 (11.5)
 Heliotropo, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (46.7) 4 (26.7) 5 (33.3) 1 (16.7) 7 (16.7) 4 (9.5) 5 (12.5) 1 (3.8)
Medications in use
 Costicosteroids, n (%) 5 (18.8) 5 (18.5) 5 (20.0) 5 (25.0) 15 (100) 15 (100) 15 (100) 6 (100) 20 (47.6) 20 (47.6) 19 11 (42.3)
 Oral Prednisone, n (%) [median dose] 5 (18.5) [15] 5 (18.5) [5] 5 (20.0) [10] 5 (25.0) [5] 12 (80) [20] 13 (86.7) [10] 12 (80) [10] 5 (83.3) [10] 17 (40,5) [15] 18 (42.9) [10] 16 (40) [10] 10 (38.5) [6.25]
 IV Methylprednisolone, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (33.3) 3 (20) 3 (20) 1 (16.7) 5 (11.9) 3 (7.1) 3 (7,5) 1 (3.8)
 Hydroxychloroquine, n (%) 9 (33.3) 8 (29.6) 8 (32.0) 4 (20.0) 8 (53.3) 10 (66.7) 10 (66.7) 4 (66.7) 17 (40.5) 18 (42.9) 18 (45) 8 (30.8)
 Methotrexate, n (%) 6 (22.2) 5 (18.8) 6 (24.0) 4 (20.0) 9 (60) 10 (66.7) 9 (60) 3 (50) 15 (35.7) 15 (35.7) 15 (37.5) 7 (26.9)
 Azathioprine, n (%) 5 (18.8) 4 (14.8) 5 (20.0) 3 (15.0) 3 (20) 3 (20) 3 (20) 2 (33.3) 8 (19) 7 (16.7) 8 (20) 5 (19.2)
 Mycophenolate Mofetil, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 1 (6.7) 2 (13.3) 1 (16.7) 1 (2.4) 1 (2.4) 2 (5) 1 (3.8)
 Cyclosporine, n (%) 3 (11.1) 3 (11.1) 3 (12.0) 3 (15.0) 4 (26.7) 4 (26.7) 3 (20) 0 (0.0) 7 (16.7) 7 (16.7) 6 (15) 3 (11.5)
 Cyclophosphamide, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 1 (6.7) 0 (0.0) 0 (0.0) 1 (2.4) 1 (2.4) 0 (0.0) 0 (0.0)
 Human Immunoglobulin, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (13.3) 2 (13.3) 0 (0.0) 0 (0.0) 2 (4.8) 2 (4.8) 0 (0.0) 0 (0.0)
 No medication, n (%) 11 (40.7) 13 (48.1) 11 (44.0) 8 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 11 (26,2) 13 (31) 11 (27.5) 8 (30.8)
  1. JDM juvenile dermatomyositis, qHPV quadrivalent human papillomavirus vaccine, CMAS childhood myositis activity score, IV intravenous
  2. aV1: baseline visit; V2: visit after the second dose; V3: visit after the third dose; V4: visit 6 months after the third dose
  3. bFive patients who had received doses of the vaccine before the study inclusion were excluded from the analysis of the baseline visit